Juno Therapeutics Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Juno Therapeutics (JUNO) Misses Q2 EPS by 23c
August 4, 2016 4:45 PM EDTJuno Therapeutics (NASDAQ: JUNO) reported Q2 EPS of ($0.64), $0.23 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $27.6 million versus the consensus estimate of $14.26 million.
For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.
... More